1
|
Da L, Tarasenko Y, Chen C. Asian American sub-ethnic disparities and trends in epithelial ovarian cancer diagnosis, treatment and survival. ETHNICITY & HEALTH 2024; 29:685-702. [PMID: 38967965 DOI: 10.1080/13557858.2024.2359387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 05/20/2024] [Indexed: 07/06/2024]
Abstract
OBJECTIVES Studies on ovarian cancer (OC) diagnosis, treatment and survival across disaggregated Asian sub-ethnic groups are sparse. Few studies have also conducted trend analyses of these outcomes within and across Asian groups. METHODS Using logistic, Cox, and Joinpoint regression analyses of the 2000-2018 Surveillance, Epidemiology, and End Results (SEER) data, we examined disparities and trends in OC advanced stage diagnosis, receipt of treatments and the 5-year cause-specific survival across seven Asian sub-ethnic groups. RESULTS There were 6491 OC patients across seven Asian sub-ethnic groups (mean [SD] age, 57.29 [13.90] years). There were 1583(24.39%) Filipino, 1183(18.23%) Chinese, and 761(11.72%) Asian Indian or Pakistani (AIP) patients. The majority (52.49%) were diagnosed with OC with at an advanced stage. AIP were more likely to have advanced stage diagnosis than other subgroups (ORs, 95%CIs: 0.77, 0.62-0.96 [Filipino]; 0.76, 0.60-0.95 [Chinese]; 0.71, 0.54-0.94 [Japanese]; 0.74, 0.56-0.98 [Vietnamese] and 0.66, 0.53-0.83 [Other Asians]). The Filipinos were least likely to receive surgery but most likely to undergo chemotherapy. Japanese patients had the worst 5-year OC cause-specific survival (50.29%, 95%CI: 46.20%-54.74%). Based on the aggregated analyses, there was a significantly decreased trend in advanced-stage diagnosis and an increased trend in receipt of chemotherapy. Trends in OC outcomes for several subethnicities differed from those observed in aggregated analyses. CONCLUSION In this cohort study of 6491 patients, OC diagnosis, treatment, survival, and trends differed across Asian American ethnic subgroups. Such differences must be considered in future research and interventions to ensure all Asian American subethnicities equally benefit from the advancements in OC care and control.
Collapse
Affiliation(s)
- Lijuan Da
- School of Public Health, Zhejiang University, Hangzhou, People's Republic of China
| | - Yelena Tarasenko
- Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of Public Health, Georgia Southern University (GSU), Statesboro, USA
| | - Chen Chen
- Department of Big Data in Health Science, School of Public Health, Zhejiang University, Hangzhou, People's Republic of China
- Center for Biostatistics, Bioinformatics, and Big Data, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China
- Department of Biostatistics, GoBroad Research Center, Shanghai, People's Republic of China
| |
Collapse
|
2
|
Gomes FDC, Figueiredo ERL, Araújo END, Andrade EMD, Carneiro CDL, Almeida GMD, Dias HAAL, Teixeira LIB, Almeida MT, Farias MFD, Linhares NA, Fonseca NLD, Pereira YDS, Melo-Neto JSD. Social, Genetics and Histopathological Factors Related to Titin ( TTN) Gene Mutation and Survival in Women with Ovarian Serous Cystadenocarcinoma: Bioinformatics Analysis. Genes (Basel) 2023; 14:genes14051092. [PMID: 37239452 DOI: 10.3390/genes14051092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2022] [Revised: 03/11/2023] [Accepted: 03/18/2023] [Indexed: 05/28/2023] Open
Abstract
Several factors may increase the risk of development of ovarian cancer. In this study, we investigated the relationship between social, genetic, and histopathologic factors in women with ovarian serous cystadenocarcinoma and titin (TTN) mutations, whether the TTN gene mutation may be a predictor, and its impact on mortality and survival in these patients. A total of 585 samples from patients with ovarian serous cystadenocarcinoma were collected from The Cancer Genome Atlas and PanCancer Atlas through the cBioPortal for analysis of social, genetic, and histopathological factors. Logistic regression was used to investigate whether TTN mutation could be a predictor, and the Kaplan-Meier method was applied to analyze survival time. TTN mutation frequency did not differ between age at diagnosis, tumor stage, and race, and was related to increased Buffa hypoxia score (p = 0.004), mutation count (p < 0.0001), Winter hypoxia Score (p = 0.030), nonsynonymous tumor mutation burden (TMB) (p < 0.0001), and reduced microsatellite instability sensor score (p = 0.010). The number of mutations (p < 0.0001) and winter hypoxia score (p = 0.008) were positively associated with TTN mutations, and nonsynonymous TMB (p < 0.0001) proved to be a predictor. Mutated TTN affects the score of genetic variables involved in cancer cell metabolism in ovarian cystadenocarcinoma.
Collapse
Affiliation(s)
- Fabiana de Campos Gomes
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
- Faculty of Medicine CERES (FACERES), São José do Rio Preto 15090-305, SP, Brazil
| | - Eric Renato Lima Figueiredo
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - Ediane Nunes De Araújo
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - Edila Monteiro De Andrade
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - Carlos Diego Lisbôa Carneiro
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - Gabriel Mácola De Almeida
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - Helana Augusta Andrade Leal Dias
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - Lucélia Inoue Bispo Teixeira
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - Manuela Trindade Almeida
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - Mariusa Fernandes De Farias
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - Natália Albim Linhares
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - Natasha Lima Da Fonseca
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - Yago Dos Santos Pereira
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| | - João Simão de Melo-Neto
- Postgraduate Program in Health, Environment and Society in the Amazon (PPGSAS), Federal University of Pará (UFPA), Street Augusto Corrêa, 01, University City: José Silveira Neto, Health sector: Guamá, Belém 66075-110, PA, Brazil
| |
Collapse
|
4
|
Donohoe F, O'Meara Y, Roberts A, Comerford L, Kelly CM, Walshe JM, Peate M, Hickey M, Brennan DJ. The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer - Trial protocol of a phase II study. Contemp Clin Trials Commun 2021; 24:100865. [PMID: 34869938 PMCID: PMC8626829 DOI: 10.1016/j.conctc.2021.100865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 10/06/2021] [Accepted: 11/09/2021] [Indexed: 11/13/2022] Open
Abstract
Aims This study will aim to assess if a composite intervention which involves a specific evidence-based intervention for management of insomnia and non-hormonal pharmacotherapy to manage vasomotor symptoms (VMS) of menopause can improve quality of life for patients experiencing troublesome VMS after cancer who are not eligible for standard systemic menopausal hormone therapy (MHT). Participants will be asked to nominate a partner or companion to support them during this process as an additional form of support. Background The menopause transition and its symptoms represent a significant challenge for many patients after cancer treatment, particularly those for whom conventional MHT is contraindicated. These symptoms include hot flushes, night sweats, urogenital symptoms as well as mood and sleep disturbance. These symptoms can exacerbate the consequences of cancer and its treatment. Methods We will recruit 205 women who meet inclusion criteria and enrol them on a composite intervention which consists of four parts: (1) use of non-hormonal pharmacotherapy for the management of troublesome vasomotor symptoms of menopause tailored to the timing of predominant symptoms, (2) digital cognitive behavioural therapy for insomnia through the web based Sleepio service, (3) access to information regarding self-management strategies for the common symptoms of menopause and their consequences and (4) identification of a partner or other support person who commits to providing support during the study period. Outcomes The primary outcome will be cancer specific quality of life measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30). Secondary outcomes will include sleep quality, bother/interference of vasomotor symptoms and communication between couples about their cancer diagnosis and their menopause experience. Sleep will be measured using the Sleep Condition Indicator (SCI) tool, bother/interference of vasomotor symptoms will be measured by the Hot Flush Rating Scale (HFRS) and communication will be measured using the Couples’ Illness Communication Scale (CICS). These validated scales will be administered at baseline, four weeks, three months and six months. Registration This study is registered on ClinicalTrials.gov with number NCT 04766229.
Collapse
Affiliation(s)
- Fionán Donohoe
- UCD Gynaecological Oncology Group, UCD School of Medicine, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
| | - Yvonne O'Meara
- UCD Gynaecological Oncology Group, UCD School of Medicine, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
| | - Aidin Roberts
- UCD Gynaecological Oncology Group, UCD School of Medicine, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
| | - Louise Comerford
- UCD Gynaecological Oncology Group, UCD School of Medicine, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
| | - Catherine M Kelly
- Dept. of Medical Oncology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
| | - Janice M Walshe
- Dept. of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland
| | - Michelle Peate
- Dept. of Obstetrics and Gynaecology, University of Melbourne, Royal Women's Hospital, Victoria, Australia
| | - Martha Hickey
- Dept. of Obstetrics and Gynaecology, University of Melbourne, Royal Women's Hospital, Victoria, Australia
| | - Donal J Brennan
- UCD Gynaecological Oncology Group, UCD School of Medicine, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
| |
Collapse
|